menu
    • menu
    [{"orgOrder":0,"company":"Imcyse","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Imcyse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imcyse \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Imcyse \/ Pfizer Inc"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Walloon Region","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"HY-083","moa":"TRPV1","graph1":"Immunology","graph2":"Preclinical","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hyloris Pharmaceuticals \/ Walloon Region","highestDevelopmentStatusID":"4","companyTruncated":"Hyloris Pharmaceuticals \/ Walloon Region"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioSenic

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            BioSenic

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Gestys Santé Biotech

                            Deal Size : $0.5 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            BioSenic Raises €500,000 in Private Placement of New Shares with Established New Investors

                            Details : BioSenic will use proceeds for a Phase 3 trial with Arscimed (oral arsenic trioxide) for first-line treatment of chronic graft-versus-host disease.

                            Product Name : Arscimed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 02, 2024

                            Lead Product(s) : Arsenic Trioxide

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Gestys Santé Biotech

                            Deal Size : $0.5 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hyloris Pharmaceuticals

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            Hyloris Pharmaceuticals

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HY-083

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Walloon Region

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Hyloris has been Granted EUR 1 Million in Non-Dilutive Funding from the Walloon Region

                            Details : The funding will be used for the first part of the development of HY-083, a TRPV1 agonist, administered intranasally as a spray, for the treatment of idiopathic rhinitis.

                            Product Name : HY-083

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 06, 2023

                            Lead Product(s) : HY-083

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Walloon Region

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Imcyse

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed

                            Imcyse

                            Belgium arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : $180.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in R...

                            Details : Imcyse and Pfizer will collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis. Pfizer will lead clinical development and commercialization activities.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 02, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Pfizer Inc

                            Deal Size : $180.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth